eCite Digital Repository

Corifollitropin alfa versus follitropin beta: an economic analysis alongside a randomized controlled trial in women undergoing IVF/ICSI

Citation

Khoa, LD and Lan, VTN and Loc, NMT and Vinh, DQ and Tran, QN and Tuong, HM, Corifollitropin alfa versus follitropin beta: an economic analysis alongside a randomized controlled trial in women undergoing IVF/ICSI, Reproductive Biomedicine and Society Online, 10 pp. 28-36. ISSN 2405-6618 (2020) [Refereed Article]


Preview
PDF
1Mb
  

Copyright Statement

2020 The Authors. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) http://creativecommons.org/licenses/by-nc-nd/4.0/

DOI: doi:10.1016/j.rbms.2020.01.002

Abstract

This cost-effectiveness analysis was conducted from the patient's perspective alongside a randomized controlled trial comparing corifollitropin alfa with follitropin beta for a single stimulation cycle. Only unit costs paid by patients are included in this analysis. The incremental cost-effectiveness ratio was calculated. One-way sensitivity analysis and probabilistic sensitivity analysis (PSA) were also performed. Baseline characteristics (except for the number of follicles and frozen embryos), treatment outcomes and complications were similar in the two groups. The live birth rate was comparable between the two groups, but the mean total cost per patient was higher for the corifollitropin alfa strategy (4293) compared with the follitropin beta strategy (4086). Costs per live birth were 13,726 and 12,511, respectively. The difference in effect between corifollitropin alfa and collitropin beta was three fewer live births, and the difference in costs was 24,048. The probability of live birth after the first and second embryo transfers and the proportion of patients who had no more frozen embryos available after non-achievement of live birth in the first or second transfer influenced the comparative cost-effectiveness of the two strategies. PSA showed that a corifollitropin alfa strategy would be rejected in up to 27.4% of scenarios. Follitropin beta 300 IU/day was more cost-effective than corifollitropin alfa 150 μg in women aged 35-42 years weighing ≥ 50 kg undergoing in-vitro fertilzation/intracytoplasmic sperm injection.

Item Details

Item Type:Refereed Article
Keywords:ICSI, IVF, corifollitropin alfa, cost-effectiveness, follitropin beta
Research Division:Biomedical and Clinical Sciences
Research Group:Reproductive medicine
Research Field:Reproduction
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Tran, QN (Mr Nhat Tran)
ID Code:139356
Year Published:2020
Deposited By:Menzies Institute for Medical Research
Deposited On:2020-06-11
Last Modified:2021-03-25
Downloads:2 View Download Statistics

Repository Staff Only: item control page